Knight Therapeutics (OTCMKTS:KHTRF) (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.
Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development. These collaborations enable the company to bring established and emerging products to market by leveraging its local regulatory expertise and commercial infrastructure.
Since its inception, Knight has grown its footprint through a combination of in-licensing agreements and strategic acquisitions, guided by its Chairman and Chief Executive Officer, Jonathan Ross Goodman. Under his leadership, the company has focused on identifying high-value assets and optimizing life-cycle management to drive sustainable growth and improve patient access to specialty pharmaceuticals.
Knight’s business model is built around a lean operating platform that supports efficient product launches, regulatory compliance and market penetration. Looking ahead, the company continues to pursue opportunities to expand its product offering in high-growth therapeutic segments and deepen its presence across the Americas.
